In the context of SCC, FAK TKIs have demonstrated efficacy in enhancing tumor management by reducing the presence of tumor-infiltrating Treg cells and surging the infiltration of CD8+ CTLs [112]. This evidence concerns the gene CD8A and neoplasm.